Managing patients with von willebrand disease type 1, 2 and 3 with desmopressin and von willebrand factor-factor VIII concentrate in surgical settings

Acta Haematologica

Volumn 121, Issue 2-3, 2009, Pages 167-176

  Michiels, Jan Jacques ^a,c,d   Van Vliet, Huub H D M ^b   Berneman, Zwi ^a   Schroyens, Wilfried ^a   Gadisseur, Alain ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Goodheart Institute   (Netherlands)

^d Hemostasis Thrombosis Science Center   (Netherlands)

Author keywords

Bleeding severity; Desmopressin; Pharmacokinetic studies; Trauma; Von Willebrand factor factor VIII concentrates

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; COLLAGEN; DESMOPRESSIN; RISTOCETIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; ARGIPRESSIN[1 DEAMINO]; BLOOD CLOTTING FACTOR 8;

BLEEDING; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE; BLEEDING TIME; CLASSIFICATION; DRUG COMBINATION; DRUG EFFECT; GENETICS; GENOTYPE; METABOLISM; PEROPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREMEDICATION; PROSPECTIVE STUDY; PROTEIN QUATERNARY STRUCTURE;

BLEEDING TIME; BLOOD LOSS, SURGICAL; COLLAGEN; DEAMINO ARGININE VASOPRESSIN; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FACTOR VIII; GENOTYPE; HUMANS; INTRAOPERATIVE CARE; PLATELET AGGREGATION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINES AS TOPIC; PREANESTHETIC MEDICATION; PROSPECTIVE STUDIES; PROTEIN STRUCTURE, QUATERNARY; RISTOCETIN; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 67649657871     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214857     Document Type: Review

References (30)

1. Federici AB, Mannucci PM: Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Haemophilia 1998; 4(suppl 3):7-10.
2. Zimmerman TS, Ruggeri ZM: von Willebrand's disease. Clin Haematol 1983; 12:175- 200.
3. Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA: Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood 1984;63:128-139.
4. Pasi KJ, Collins PW, Keeling DM, Brown SA, Cumming AM, Dolan GC, Hay CR, Hill FG, Laffan M, Peake IR: Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10:218-231.
5. Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 2000; 6(suppl 1): 60-67.
6. Mannucci PM, Aberg M, Nilsson IM, Robertson B: Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975;30 81-93.
7. Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E: Platelet aggregation induced by 1-desamino-8-D -arginine vasopressin (DDAVP) in type IIB von Willebrand's disease. N Engl J Med 1983;309:816-821.
8. Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM: Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103:2032-2038.
9. Lethagen S, Harris AS, Sjorin E, Nilsson IM: Intranasal and intravenous administration of desmopressin: effect on FVIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987;58:1033-1036.
10. Kohler M, Hellstern P, Tarrach H, Bambauer R, Wenzel E, Jutzler GA: Subcutaneous injection of desmopressin (DDAVP): evaluation of a new, more concentrated preparation. Haemostasis 1989; 19:38-44.
11. Michiels JJ, van de Velden A, van Vliet HHDM, van der Planken M, Schroyens W, Berneman Z: Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002; 28:111-131.
12. Michiels JJ, van Vliet HHDM, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U: Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleeding in patients with von Willebrand disease type 1, 2 and 3. Clin Appl Thromb Hemost 2007; 13:14-34.
13. De La Fuente B, Kaspar CK, Rickless FR, Hoyer LW: Response of patients with mild and moderate hemophilia and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 1985; 103:6-14.
14. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero F: Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from t h e Europea n MCMDM-1VWD. Blood 2008; 111:3531-3539.
15. Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, Berneman Z: Guidelines for the evaluation of intravenous desmopressin and von Willebrand/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2 and 3. Semin Thromb Hemost 2006;32:636-643.
16. Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP: von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171-232.
17. Goudemand J, Scharrer I, Berntorp E, Lee CA, Borel-Derlon A, Stieltjes N, Caron C, Scherrmann JM, Bridey F, Tellier Z, Federici AB, Mannucci PM: Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 2005;3:2219- 2227.
18. Lethagen S, Carlson M, Hillarp A: A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10:243-249.
19. Budde U, Metzner HJ, Müller HG: Comparative analysis and classification of von Wille-brand factor/factor VIIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost 2006; 32:626-635.
20. Mannucci PM: Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-694.
21. Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, Römisch J, Svae TE: Characterisation of a novel high-purity, double virus inactivated von Willebrand factor and factor VIII concentrate (Wilate®). Biologicals 2006; 34:281-288.
22. Michiels JJ, Berneman Z, van der Planken M, Schroyens W, Budde U, van Vliet HHDM: Bleeding prophylaxis for major surgery in patients with an intermediate purity factor VIII-von Willebrand concentrate (Haemate-P). Blood Coagul Fibrinolysis 2004; 15:323-330.
23. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM: von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007;5:1420-1430.
24. Dobrkovska A, Krzensk U, Chediak JR: Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998; 4(suppl):33-39.
25. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA: Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willlebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87:224-230.
26. Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C, Alphanate Study Group: Treatment of von Willebrand disease with high-purity factor VIII/ von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 450-456.
27. Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G: Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica 2003;88:1279-1283.
28. Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten F, Schwartz BA, Humate-P Study Group: Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/von Willebrand concentrate (Humate-P). Haemophilia 2004;10:42-51.
29. Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM: Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007;5:1115-1124.
30. Federici AB, Castaman G, Franchini M, Morfini M, Zanon E, Coppola A, Tagliaferri A, Boeri E, Mazzucconi MG, Rossetti G, Mannucci PM: Clinical use of Haemate-P in inherited von Willebrand's disease: a cohort of 100 Italian patients. Haematologica 2007; 92:944-951.